HLB Pharmaceutical Decides on 19 Billion KRW Capital Increase

On April 24, HLB Pharmaceutical announced that it will conduct a third-party allotment capital increase worth 19 billion KRW. The purpose of this new share issuance is to raise funds for operating capital and other financial needs. The issue price for the new shares is 19,460 KRW per share. A total of 976,362 common shares will be issued. All of the newly issued shares will be allotted to HLB Life Science, the largest shareholder.